Evidence map›Paper›PMID 32664944›Full record

ReviewBMC medicine2020

Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.

Giovanni Ostuzzi, Davide Papola, Chiara Gastaldon, Georgios Schoretsanitis, Federico Bertolini, Francesco Amaddeo, Alessandro Cuomo, Robin Emsley, Andrea Fagiolini, Giuseppe Imperadore and 12 more

Erratum issuedOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 4 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Did the COVID-19 Pandemic Affect the Use of Antipsychotics Among Nursing Home Residents With ADRD?The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2023
    Observational
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 8 countries.

Giovanni OstuzziWHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy. giovanni.ostuzzi@univr.it.ORCID http://orcid.org/0000-0003-2248-9524
Davide PapolaWHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
Chiara GastaldonWHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
Georgios SchoretsanitisDepartment of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.
Federico BertoliniWHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
Francesco AmaddeoWHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
Alessandro CuomoDepartment of Molecular Medicine, University of Siena, Siena, Italy.
Robin EmsleyDepartment of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg Campus, Cape Town, 8000, South Africa.
Andrea FagioliniDepartment of Molecular Medicine, University of Siena, Siena, Italy.
Giuseppe ImperadoreAzienda ULSS 9 Scaligera, Verona, Italy.
Taishiro KishimotoDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Giulia MichencighWHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
Michela NoséWHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
Marianna PurgatoWHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
Serdar DursunDepartment of Psychiatry, University of Alberta, Edmonton, Alberta, Canada.
Brendon StubbsDepartment of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.
David TaylorPharmacy Department, Maudsley Hospital, London, UK.
Graham ThornicroftCentre for Global Mental Health and Centre for Implementation Science, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Philip B WardSchool of Psychiatry, UNSW Sydney and Schizophrenia Research Unit, Ingham Institute of Applied Medical Research, Liverpool, NSW, Australia.
Christoph HiemkeDepartment of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany.
Christoph U CorrellDepartment of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.
Corrado BarbuiWHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.
University of Verona · ITNorthwell Health · USUniversity of Siena · ITAULSS 2 Marca Trevigiana · ITJohannes Gutenberg University Mainz · DEKeio University · JPKing's College London · GBMaudsley Hospital · GBNational Health Service · GBStellenbosch University · ZAUniversity of Alberta · CAUNSW Sydney · AU

Funding

Medical Research Council MR/R023697/1Medical Research Council MR/S001255/1
6 · The paper itself

Abstract

backgroundThe novel coronavirus pandemic calls for a rapid adaptation of conventional medical practices to meet the evolving needs of such vulnerable patients. People with coronavirus disease (COVID-19) may frequently require treatment with psychotropic medications, but are at the same time at higher risk for safety issues because of the complex underlying medical condition and the potential interaction with medical treatments.

methodsIn order to produce evidence-based practical recommendations on the optimal management of psychotropic medications in people with COVID-19, an international, multi-disciplinary working group was established. The methodology of the WHO Rapid Advice Guidelines in the context of a public health emergency and the principles of the AGREE statement were followed. Available evidence informing on the risk of respiratory, cardiovascular, infective, hemostatic, and consciousness alterations related to the use of psychotropic medications, and drug-drug interactions between psychotropic and medical treatments used in people with COVID-19, was reviewed and discussed by the working group.

resultsAll classes of psychotropic medications showed potentially relevant safety risks for people with COVID-19. A set of practical recommendations was drawn in order to inform frontline clinicians on the assessment of the anticipated risk of psychotropic-related unfavorable events, and the possible actions to take in order to effectively manage this risk, such as when it is appropriate to avoid, withdraw, switch, or adjust the dose of the medication.

conclusionsThe present evidence-based recommendations will improve the quality of psychiatric care in people with COVID-19, allowing an appropriate management of the medical condition without worsening the psychiatric condition and vice versa.

Indexed as

Drug InteractionsBetacoronavirusCoronavirus InfectionsCOVID-19Evidence-Based MedicineHumansMental DisordersPandemicsPneumonia, ViralPsychotropic DrugsPublic HealthRandomized Controlled Trials as TopicRiskSARS-CoV-2Systematic Reviews as TopicPsychotropic DrugsCOVID-19Drug–drug interactionsNovel coronavirusPsychiatric comorbidityPsychopharmacology

Identifiers

PMID32664944
PMCPMC7360478
OpenAlexW3043525935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.